Circle has acquired nearly 1,000 blockchain patents from IBM, giving the USDC issuer what it describes as the largest blockchain patent portfolio in the United States.
Summary
- Circle acquired nearly 1,000 issued patents spanning more than 680 patent families.
- The portfolio covers blockchain, banking, insurance, cloud security, and enterprise infrastructure.
- Circle has not disclosed the purchase price or explained whether it could enforce the patents against competitors.
- CRCL initially gained about 2%, but later fell after Morgan Stanley cut its target to $38.
Circle takes control of IBM’s blockchain portfolio
Circle announced the acquisition on July 27, saying it had purchased core assets from IBM’s blockchain patent portfolio. The transaction covers more than 680 patent families and nearly 1,000 issued patents worldwide.
The intellectual property spans blockchain systems, financial services, banking, insurance, supply-chain verification, enterprise infrastructure, and secure cloud operations. Circle did not disclose the financial terms.
Circle said the portfolio would support USDC, the Circle Payments Network, its Arc blockchain, and tools designed for artificial intelligence agents. The two companies also plan to consider further commercial agreements.
“Intellectual property is critical to advancing our mission and expanding adoption of onchain infrastructure,” Circle General Counsel Sarah Wilson said.
Wilson added that the acquisition would expand Circle’s ability to develop infrastructure for internet-based finance.
Patent deal raises concerns over possible enforcement
Circle’s announcement did not state whether the company intends to license the patents, use them defensively, or enforce them against other blockchain businesses.
That lack of detail has prompted questions about how Circle could use its newly acquired intellectual property. In an Aug. 3 commentary, Fortune’s Jeff John Roberts warned that the patents could become legal leverage against competitors or startups.
Roberts argued that Circle could theoretically seek licensing payments, bring infringement cases, or transfer patents to separate entities that pursue enforcement. However, Circle has not announced plans to take any of those actions.
The concerns also stem from IBM’s mixed record in commercial blockchain development. IBM previously backed several enterprise blockchain projects, including supply-chain and trade-finance platforms, but many failed to achieve broad adoption.
A large patent portfolio does not necessarily indicate that the underlying products reached commercial success. Still, issued US patents can give their owner the right to restrict others from using covered inventions, subject to their validity and scope.
Circle has also not announced a public defensive patent pledge comparable to commitments used by some other digital-asset companies. Such pledges generally promise that patents will not be used offensively against developers acting in good faith.
US blockchain firms face new intellectual property risk
Circle’s position as the largest US holder of blockchain-related patents could affect companies building stablecoin, payments, interoperability, and enterprise ledger products.
The practical impact will depend on the language of individual patent claims and whether Circle chooses to enforce them. Any infringement dispute would also face review in US courts, where defendants can challenge whether a patent is valid or applies to their technology.
For Circle, the acquisition may provide protection as it expands beyond reserve income from USDC. Arc, Circle Payments Network, cross-chain services, and agent-based payment tools could expose the company to a broader set of technology competitors.
It may also strengthen Circle’s bargaining position in licensing or partnership negotiations. Still, without an enforcement policy, developers and competitors have limited visibility into whether the portfolio will function mainly as a defensive shield or a commercial asset.
CRCL falls despite initial reaction to IBM deal
Fortune reported that Circle shares rose about 2% following news of the acquisition. That gain did not hold as separate concerns about the company’s USDC business weighed on CRCL on Aug. 3.
Circle shares fell nearly 5% to around $59 after Morgan Stanley downgraded the stock to underweight and cut its price target from $106 to $38. The bank cited weaker USDC supply forecasts, pressure on reserve income, and a potential shift toward lower-margin transaction revenue.
Morgan Stanley reduced its USDC supply estimates by 33% for 2027 and 44% for 2028. The downgrade was separate from the IBM patent acquisition, although both developments reflect Circle’s attempt to establish revenue sources beyond interest earned on USDC reserves.
Investors will now watch for details on how Circle intends to integrate, license, or enforce the patents. Until the company provides those details, claims that it will use the portfolio against competitors remain speculative.
